Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Transthyretin amyloid (ATTR) cardiomyopathy is a progressive and fatal disease caused by misfolded transthyretin. Despite advances in slowing disease progression, there is no available treatment that depletes ATTR from the heart for the amelioration of cardiac dysfunction. NI006 is a recombinant human anti-ATTR antibody that was developed for the removal of ATTR by phagocytic immune cells. METHODS: In this phase 1, double-blind trial, we randomly assigned (in a 2:1 ratio) 40 patients with wild-type or variant ATTR cardiomyopathy and chronic heart failure to receive intravenous infusions of either NI006 or placebo every 4 weeks for 4 months. Patients were sequentially enrolled in six cohorts that received ascending doses (ranging from 0.3 to 60 mg per kilogram of body weight). After four infusions, patients were enrolled in an open-label extension phase in which they received eight infusions of NI006 with stepwise increases in the dose. The safety and pharmacokinetic profiles of NI006 were assessed, and cardiac imaging studies were performed. RESULTS: The use of NI006 was associated with no apparent drug-related serious adverse events. The pharmacokinetic profile of NI006 was consistent with that of an IgG antibody, and no antidrug antibodies were detected. At doses of at least 10 mg per kilogram, cardiac tracer uptake on scintigraphy and extracellular volume on cardiac magnetic resonance imaging, both of which are imaging-based surrogate markers of cardiac amyloid load, appeared to be reduced over a period of 12 months. The median N-terminal pro-B-type natriuretic peptide and troponin T levels also seemed to be reduced. CONCLUSIONS: In this phase 1 trial of the recombinant human antibody NI006 for the treatment of patients with ATTR cardiomyopathy and heart failure, the use of NI006 was associated with no apparent drug-related serious adverse events. (Funded by Neurimmune; NI006-101 ClinicalTrials.gov number, NCT04360434.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Self-citationCRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice
Witteles, R. M., Bokhari, S., Damy, T., Elliott, P. M., Falk, R. H., Fine, N. M., Gospodinova, M., Obici, L., Rapezzi, C., & Garcia-Pavia, P. (2019) · JACC: Heart Failure · doi:10.1016/j.jchf.2019.04.010 · Cited by 351
Self-citationPrevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction
AbouEzzeddine, O. F., Davies, D. R., Scott, C. G., Fayyaz, A. U., Askew, J. W., McKie, P. M., Noseworthy, P. A., Johnson, G. B., Dunlay, S. M., Borlaug, B. A., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.3070 · Cited by 220
Cited by
2023 ESC guidelines for the management of cardiomyopathies
Arbelo, E., Protonotarios, A., Gimeno, J. R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C. R., Biagini, E., Blom, N. A., de Boer, R. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad194 · Cited by 2,844
Self-citationApplications of Gene Therapy in Cardiomyopathies
Argiro, A., Bui, Q., Hong, K. N., Ammirati, E., Olivotto, I., & Adler, E. (2024) · JACC: Heart Failure · doi:10.1016/j.jchf.2023.09.015 · Cited by 59
Oikonomou, E. K., Sangha, V., Vasisht Shankar, S., Coppi, A., Krumholz, H. M., Nasir, K., Miller, E. J., Gallegos-Kattan, C., Al-Mallah, M. H., Al-Kindi, S., et al. (2024) · doi:10.1101/2024.08.25.24312556 · Cited by 7
Metadata
- Authors
- Garcia-Pavia, P., aus dem Siepen, F., Donal, E., Lairez, O., van der Meer, P., Kristen, A. V., Mercuri, M. F., Michalon, A., Frost, R. J. A., Grimm, J., Nitsch, R. M., Hock, C., Kahr, P. C., & Damy, T.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-07-20
- Volume
- 389
- Issue
- 3
- Pages
- 239-250
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4377137084
- Cited by
- 248
- References
- 4
- FWCI
- 18.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. https://app.cochat.ai/papers/10.1056/nejmoa2303765
- The paper
- Garcia-Pavia, P., aus dem Siepen, F., Donal, E., Lairez, O., van der Meer, P., Kristen, A. V., Mercuri, M. F., Michalon, A., Frost, R. J. A., Grimm, J., Nitsch, R. M., Hock, C., Kahr, P. C., & Damy, T. (2023). Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2303765
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.